COMMUNIQUÉS West-GlobeNewswire

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics

28/06/2017 - 13:00

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics Funding to advance gene therapies targeting orphan paediatric disorders through clinical trials LONDON, 28 June, 2017: Arix [...]

Medtronic SureTune(TM)3 Earns CE Mark for Deep Brain Stimulation Therapy

28/06/2017 - 13:00

Data Presented at the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery in Berlin DUBLIN and BERLIN - June 28, 2017 - Medtronic plc (NYSE: MDT) today announced it has received CE [...]

Summit Therapeutics plc : Grant of Share Options

28/06/2017 - 08:00

Summit Therapeutics plc ("Summit" or the "Company") GRANT OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for [...]

Summit Therapeutics plc : Exercise of Share Options

28/06/2017 - 08:00

Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies [...]

MITHRA SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH FUJI PHARMA FOR DONESTA® IN JAPAN AND ASEAN

28/06/2017 - 07:30

Mithra signs EXclusive license and supply agreement with FUJI Pharma for donesta® in japan and asean Fuji Pharma obtains rights to commercialize Donesta®, Mithra's Hormone Therapy (HT) product candidate based on [...]

MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer

28/06/2017 - 07:00

NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 28 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced its activities at the fifth Global Congress on [...]

MDxHealth présente trois études SelectMDx lors du 5e congrès mondial sur le cancer de la prostate

28/06/2017 - 07:00

COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 AM CEST - Le 28 juin 2017 - MDxHealth SA (Euronext: MDXH.BR) a annoncé aujourd'hui ses activités lors [...]

Minerva Neurosciences, Inc. to Offer Common Shares

27/06/2017 - 22:10

WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 5,000,000 shares of its common [...]

La demande relative aux interventions de chirurgie esthétique dans le monde continue de s'envoler : les États Unis, le Brésil, le Japon, l'Italie et le Mexique classés comme les cinq principaux pays

27/06/2017 - 20:25

NEW YORK, le 27 juin 2017 (GLOBE NEWSWIRE) - L'International Society of Aesthetic Plastic Surgery (ISAPS) a publié aujourd'hui les résultats de son enquête annuelle mondiale (Global Aesthetic Survey) sur les [...]

Nestlé outlines future value creation model including strategic growth priorities and supporting capital structure

27/06/2017 - 18:01

This press release is also available in Français (pdf) and Deutsch (pdf) ....................................... Vevey, 27 June 2017 Nestlé outlines future value creation model including strategic growth priorities and [...]

Mithra Pharmaceuticals: INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS (DENOMINATOR)

27/06/2017 - 17:45

Information on the total number of voting rights (denominator) Liège, Belgium , 27 June 2017 [ 5:45 pm CET ] - Regulated information - In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large [...]

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD

27/06/2017 - 15:00

MINNEAPOLIS, June 27, 2017 (GLOBE NEWSWIRE) -- Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 [...]

Nuvaira annonce l'achèvement de l'inscription pour le premier essai clinique à groupe témoin fictif contre la dénervation pulmonaire ciblée pour la MPOC

27/06/2017 - 15:00

MINNEAPOLIS, le 27 juin 2017 (GLOBE NEWSWIRE) - Nuvaira (anciennement connue sous le nom de Holaira), développeur de dispositifs médicaux pour traiter les maladies pulmonaires obstructives, a annoncé aujourd'hui l' [...]

Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine

27/06/2017 - 13:59

Company to host conference call at 3 pm CEST (9 am EDT) today to review study results First RSV vaccine to show immunogenicity against five distinct RSV proteins 421 subject study shows vaccine was well tolerated at all [...]

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio

27/06/2017 - 13:00

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio Series A finance raised by high quality investor syndicate for neurodegenerative diseases therapies LONDON, 27 June, 2017: Arix Bioscience plc (LSE [...]

Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017

27/06/2017 - 11:00

Heidelberg, Germany, June 27, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation [...]

Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries

27/06/2017 - 10:00

NEW YORK, June 27, 2017 (GLOBE NEWSWIRE) -- The International Society of Aesthetic Plastic Surgery (ISAPS) today released the results of their annual Global Aesthetic Survey for procedures completed in 2016, which [...]

Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA

27/06/2017 - 08:00

Company announcement, Helsinki, 27 June 2017 at 9 am Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a [...]

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

27/06/2017 - 08:00

Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical- [...]